ACST logo

Acasti Pharma (ACST) Long Term Liabilities

ACST Annual Total Long Term Liabilities

$9.87 M
+$2.12 M+27.28%

31 March 2024

ACST Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

ACST Quarterly Long Term Liabilities

$6.54 M
-$1.21 M-15.64%

30 September 2024

ACST Quarterly Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

ACST Long Term Liabilities Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+27.3%-35.0%
3 y3 years+89.2%+486.1%
5 y5 years-19.0%-64.1%

ACST Long Term Liabilities High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year
5 y5-year
alltimeall time-42.2%-72.2%

Acasti Pharma Long Term Liabilities History

DateAnnualQuarterly
Sept 2024
-
$6.54 M(-15.6%)
June 2024
-
$7.75 M(-21.5%)
Mar 2024
$9.87 M(+27.3%)
$9.87 M(+1.4%)
Dec 2023
-
$9.73 M(-3.3%)
Sept 2023
-
$10.07 M(+42.7%)
June 2023
-
$7.06 M(-9.0%)
Mar 2023
$7.76 M(-54.6%)
$7.76 M(-53.4%)
Dec 2022
-
$16.65 M(-1.7%)
Sept 2022
-
$16.94 M(+0.7%)
June 2022
-
$16.82 M(-1.6%)
Mar 2022
$17.09 M(+227.5%)
$17.09 M(+6276.9%)
Dec 2021
-
$268.00 K(-76.0%)
Sept 2021
-
$1.12 M(-76.0%)
June 2021
-
$4.65 M(-10.9%)
Mar 2021
$5.22 M(+111.8%)
$5.22 M(+123.0%)
Dec 2020
-
$2.34 M(+93.7%)
Sept 2020
-
$1.21 M(-61.4%)
June 2020
-
$3.13 M(+26.9%)
Mar 2020
$2.46 M(-79.8%)
$2.46 M(-89.5%)
Dec 2019
-
$23.55 M(+29.1%)
Sept 2019
-
$18.23 M(+36.9%)
June 2019
-
$13.32 M(+9.3%)
Mar 2019
$12.18 M(+95.7%)
$12.18 M(+9.3%)
Dec 2018
-
$11.15 M(-33.2%)
Sept 2018
-
$16.69 M(+140.5%)
June 2018
-
$6.94 M(+11.5%)
Mar 2018
$6.22 M(+414.0%)
$6.22 M(+8.8%)
Dec 2017
-
$5.72 M(+355.0%)
Sept 2017
-
$1.26 M(+6.7%)
June 2017
-
$1.18 M
DateAnnualQuarterly
Mar 2017
$1.21 M(+952.1%)
-
Nov 2016
-
$44.70 K(+0.7%)
Aug 2016
-
$44.40 K(-53.2%)
May 2016
-
$94.80 K(-17.6%)
Feb 2016
$115.10 K(-93.9%)
$115.10 K(-43.1%)
Nov 2015
-
$202.40 K(-57.1%)
Aug 2015
-
$472.20 K(-9.6%)
May 2015
-
$522.20 K(-72.3%)
Feb 2015
$1.88 M(-81.3%)
$1.88 M(+30.5%)
Nov 2014
-
$1.44 M(-77.1%)
Aug 2014
-
$6.31 M(+4.6%)
May 2014
-
$6.03 M(-40.0%)
Feb 2014
$10.05 M(>+9900.0%)
$10.05 M(>+9900.0%)
Nov 2013
-
$0.00(0.0%)
Aug 2013
-
$0.00(0.0%)
May 2013
-
$0.00(0.0%)
Feb 2013
$0.00(0.0%)
$0.00(0.0%)
Nov 2012
-
$0.00(0.0%)
Aug 2012
-
$0.00(0.0%)
May 2012
-
$0.00(0.0%)
Feb 2012
$0.00(0.0%)
$0.00(0.0%)
Nov 2011
-
$0.00(0.0%)
Aug 2011
-
$0.00(-100.0%)
May 2011
-
$182.80 K(>+9900.0%)
Feb 2011
$0.00(0.0%)
$0.00(0.0%)
Nov 2010
-
$0.00(0.0%)
Aug 2010
-
$0.00(0.0%)
May 2010
-
$0.00(0.0%)
Feb 2010
$0.00
$0.00(0.0%)
Nov 2009
-
$0.00

FAQ

  • What is Acasti Pharma annual total long term liabilities?
  • What is the all time high annual total long term liabilities for Acasti Pharma?
  • What is Acasti Pharma annual total long term liabilities year-on-year change?
  • What is Acasti Pharma quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for Acasti Pharma?
  • What is Acasti Pharma quarterly long term liabilities year-on-year change?

What is Acasti Pharma annual total long term liabilities?

The current annual total long term liabilities of ACST is $9.87 M

What is the all time high annual total long term liabilities for Acasti Pharma?

Acasti Pharma all-time high annual total long term liabilities is $17.09 M

What is Acasti Pharma annual total long term liabilities year-on-year change?

Over the past year, ACST annual total long term liabilities has changed by +$2.12 M (+27.28%)

What is Acasti Pharma quarterly total long term liabilities?

The current quarterly long term liabilities of ACST is $6.54 M

What is the all time high quarterly long term liabilities for Acasti Pharma?

Acasti Pharma all-time high quarterly total long term liabilities is $23.55 M

What is Acasti Pharma quarterly long term liabilities year-on-year change?

Over the past year, ACST quarterly total long term liabilities has changed by -$3.53 M (-35.03%)